Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · President, CEO | March 12, 2026 | August 07, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director · President, CEO | August 15, 2026 | August 18, 2026 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | EVP, Chief Operating Officer | February 02, 2021 | February 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date March 12, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 53,334 |
Reported balance
After 2026-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 53,334 · Balance 53,334 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 440,485 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 193,575 · Balance 440,485 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Mirati Therapeutics, Inc.
Report date February 02, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,638 |
Ending reported balance
After 2021-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-02 · Exercise / conversion · Acquired 1,340 · Balance 31,978 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Row 2 · 2021-02-02 · Sale · Disposed 1,340 · Balance 30,638 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.33 · Expires 2030-01-05 | Direct | 63,630 |
Reported balance
After 2021-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-02 · Exercise / conversion · Disposed 1,340 · Balance 63,630 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 38,828 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 26,250 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.62 · Expires 2026-05-01 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 7, 2026 02:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 15,309 | $43.26 | $662,267.34 |
DisclosureSEC source: 0001673528-26-000002 · form4-01072026_020125.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,139 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 34,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000002 · form4-01072026_020125.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,355 Underlying: Common Stock · 34,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 34,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673528-26-000002 · form4-01072026_020125.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 2,305 shares acquired under the Company's ESPP. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 305,500 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · derivative · entry 8 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2035-01-06 F8 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 107,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · derivative · entry 7 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,350 Underlying: Common Stock · 107,350 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,700 Underlying: Common Stock · 17,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 6,387 | $15.30 | $97,721.10 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · nonDerivative · entry 4 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,466 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 17,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 34,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,032 Underlying: Common Stock · 34,678 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 13,033 | $14.60 | $190,281.80 |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,003 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 34,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001034 · form4-01072025_100123.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 212 shares acquired under the Company's ESPP. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock · Derivative | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020039 · form4-07242024_080744.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. F2 · derivative.expiration_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 00:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 347,441 | $21.60 | $7,504,725.60 |
DisclosureSEC source: 0001415889-24-009164 · form4-03272024_120311.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,646 F2 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,000 | $21.42 | $64,267.50 |
DisclosureSEC source: 0001415889-24-009164 · form4-03272024_120311.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,087 F1 · kind: Represents shares sold by the Reporting Person to cover a portion of the tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by "sell to cover transactions" and do not represent discretionary transactions by the Reporting Person. F2 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| March 22, 2024 Filed Mar 27, 2024 00:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 145,940 | $22.78 | $3,325,184.52 |
DisclosureSEC source: 0001415889-24-009164 · form4-03272024_120311.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,087 F1 · kind: Represents shares sold by the Reporting Person to cover a portion of the tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by "sell to cover transactions" and do not represent discretionary transactions by the Reporting Person. F2 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 00:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,866 | $21.81 | $149,747.46 |
DisclosureSEC source: 0001209191-24-001277 · doc4.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898,027 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001277 · doc4.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,550 Underlying: Common Stock · 17,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001277 · doc4.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:52 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 138,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001044 · doc4.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,710 Underlying: Common Stock · 138,710 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:52 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 379,620 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001044 · doc4.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,620 Underlying: Common Stock · 379,620 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 71,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002877 · doc4.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,400 Underlying: Common Stock · 71,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 194,900 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002877 · doc4.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,900 Underlying: Common Stock · 194,900 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 887,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020792 · doc4.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,043 F1 · balance_after: Certain of the restricted stock units are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:43 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009320 · doc4.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 22:26 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (Right to Buy) · Derivative | 2,321 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001209191-21-067159 · doc4.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,321 Underlying: Common Stock · 2,321 shares Expires 2031-11-25 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on February 10, 2022, subject to the reporting person's continuous status as a director through February 10, 2022. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 22:26 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001209191-21-067159 · doc4.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-11-25 F1 · derivative.exercise_date: 1/36th of the total shares subject to the option shall vest on December 26, 2021 and 1/36th of the total shares subject to the option shall vest on each monthly anniversary thereafter, subject to the reporting person's continuous status as a director through each such date. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:09 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 1,340 | $0.00 Strike: $114.33 | $0.00 |
DisclosureSEC source: 0001214659-21-001205 · marketforms-51351.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,630 Underlying: Common Stock · 1,340 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:09 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,340 | $194.38 | $260,469.20 |
DisclosureSEC source: 0001214659-21-001205 · marketforms-51351.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,638 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:09 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 1,340 | $114.33 | $153,202.20 |
DisclosureSEC source: 0001214659-21-001205 · marketforms-51351.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:14 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,979 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000673 · marketforms-50973.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,979 Underlying: Common Stock · 10,979 shares Expires 2031-01-14 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:14 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 7,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000673 · marketforms-50973.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,638 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 2,613 | $216.33 | $565,270.29 |
DisclosureSEC source: 0001214659-21-000333 · marketforms-50910.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,615 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 12 | $215.31 | $2,583.68 |
DisclosureSEC source: 0001214659-21-000333 · marketforms-50910.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,228 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 64,970 | $0.00 Strike: $114.33 | $0.00 |
DisclosureSEC source: 0001214659-20-000227 · marketforms-47394.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,970 Underlying: Common Stock · 64,970 shares Expires 2030-01-05 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 26,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000227 · marketforms-47394.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,240 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerRestricted Stock Units · Derivative | 21,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-05-01 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $56.17 | $0.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2027-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2028-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | OtherCommon Stock | 38,828 | $114.50 | $4,445,806.00 |
DisclosureSEC source: 0000899243-19-029433 · doc4.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · derivative · entry 9 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $56.17 | $0.00 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · derivative · entry 8 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested January 18, 2018 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · derivative · entry 7 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 80,000 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 6,228 | $113.43 | $706,442.04 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 6 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,828 Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 8,750 | $50.55 | $442,312.50 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 5 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 10,325 | $113.43 | $1,171,164.75 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 14,000 | $56.17 | $786,380.00 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 51,401 | $113.42 | $5,829,901.42 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,631 Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 80,000 | $37.62 | $3,009,600.00 |
DisclosureSEC source: 0000899243-19-009062 · doc4.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.